Logo image
REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY
Journal article   Open access   Peer reviewed

REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY

Payal Kohli, Lars Wallentin, Eric Reyes, Jay Horrow, Steen Husted, Robert Storey, Stefan James and Christopher Cannon
Journal of the American College of Cardiology, v 59(13), pp E504-E504
27 Mar 2012
url
https://doi.org/10.1016/S0735-1097(12)60505-1View
Published, Version of Record (VoR) Open

Abstract

Acute coronary syndromes Angina pectoris Drug therapy Heart attacks Stroke
Background We sought to explore the effect of potent platelet inhibition on recurrent (e.g. second) and ischemic events, such as urgent revascularization (Urgent Revasc), (severe) recurrent ischemia (SRI/RI), transient ischemic attacks (TIA) and arterial thromboses (ATE).

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image